4-Bromo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile

Catalog No. :
ACLMXK654
CAS No. :
863868-31-9
Molecular Formula :
C13H15BBrNO2
Molecular Weight :
307.98

IUPAC Name:4-bromo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile

4-Bromo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-Bromo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
IUPAC Name4-bromo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
Molecular FormulaC13H15BBrNO2
Molecular Weight307.98
SMILESCC1(C)OB(C2=CC(C#N)=CC=C2Br)OC1(C)C
InChI KeyNZFROIWRZNAQLI-UHFFFAOYSA-N
Synonym4-Bromo-2-nitrilephenylboronic acid pinacol ester;4-Bromo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile;Benzonitrile, 4-bromo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;2-Bromo-5-nitrilephenylboronic acid pinacol ester
CAS No.863868-31-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACLMXK654 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACTZHK074 route compound structure diagram
    ACTZHK074188984-35-2 In Stock
  4. Then
  5. ACLMXK654 route product structure diagram
    ACLMXK654863868-31-9
Inquiry

2. ACLMXK654 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACICOA146 route compound structure diagram
    ACICOA1461006715-27-0 In Stock
  4. Then
  5. ACLMXK654 route product structure diagram
    ACLMXK654863868-31-9
Inquiry

Comments (0)